NEW YORK (360Dx) – Abcam has agreed to work with Chinese diagnostics firm Shuwen Biotech on the development and commercialization of companion diagnostics, the companies announced today.
The scope of the partnership has yet to be determined, but is expected to involve Abcam providing reproducible, highly specific recombinant antibodies against key targets, which Shuwen will incorporate into CDx kits.
Financial and other terms of the deal were not disclosed.
"Shuwen has a long-standing reputation amongst pharmaceutical companies for companion diagnostic kit development and central lab testing, and Abcam is a recognized leader in quality antibody development," Shuwen Chairman and CEO Jay Zhang said in a statement. "This alliance will undoubtedly further strengthen Shuwen's capabilities in developing quality companion diagnostic kits, especially immunoassay kits."